

# Francois Ghiringhelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5012640/publications.pdf>

Version: 2024-02-01

213  
papers

36,054  
citations

15001

68  
h-index

3941

183  
g-index

223  
all docs

223  
docs citations

223  
times ranked

43160  
citing authors

#	ARTICLE	IF	CITATIONS
1	Can the hyperthermia-mediated heat shock factor/heat shock protein 70 pathway dampen the cytokine storm during SARS-CoV-2 infection?. <i>British Journal of Pharmacology</i> , 2022, 179, 4910-4916.	2.7	6
2	<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapies. <i>Gut</i> , 2022, 71, 457-466.	6.1	87
3	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. <i>British Journal of Cancer</i> , 2022, 126, 1264-1270.	2.9	15
4	MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. <i>Cancer Cell</i> , 2022, 40, 136-152.e12.	7.7	79
5	A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota. <i>Cancer Discovery</i> , 2022, 12, 1070-1087.	7.7	86
6	Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. <i>Nature Immunology</i> , 2022, 23, 262-274.	7.0	47
7	Parallel Evolution and Differences in Seroprevalence of SARS-CoV-2 Antibody Between Cancer Patients and Health Care Workers in a Tertiary Cancer Center During First and Second Wave of COVID-19 Pandemic: canSEROcov-II Cross Sectional Study. <i>European Journal of Cancer</i> , 2022, 165, 13-24.	1.3	3
8	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	15.2	225
9	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	1.8	26
10	Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2549-2563.	2.0	24
11	Conception and Evaluation of Fluorescent Phosphine-Gold Complexes: From Synthesis to in vivo Investigations. <i>ChemMedChem</i> , 2022, , .	1.6	3
12	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
13	Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. <i>Cancers</i> , 2022, 14, 1675.	1.7	3
14	Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3343.	1.8	1
15	MAPK signaling regulates the efficacy of chemoimmunotherapy. <i>Molecular and Cellular Oncology</i> , 2022, 9, 2054652.	0.3	0
16	Mitophagy: a new actor in the efficacy of chemo-immunotherapy. <i>Autophagy</i> , 2022, 18, 3033-3034.	4.3	4
17	Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects. <i>Cancer Immunology Research</i> , 2022, 10, 900-916.	1.6	2
18	GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC) – A randomized, double-blind trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9152-TPS9152.	0.8	2



#	ARTICLE	IF	CITATIONS
37	Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. <i>Lung Cancer</i> , 2021, 161, 98-107.	0.9	1
38	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	3.3	9
39	New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases. <i>Frontiers in Immunology</i> , 2021, 12, 750407.	2.2	5
40	Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5472.	1.7	0
41	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5562.	1.7	6
42	Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images. <i>Scientific Reports</i> , 2021, 11, 23912.	1.6	13
43	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. <i>Gut</i> , 2020, 69, 531-539.	6.1	97
44	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	2.7	75
45	Immune Th17 lymphocytes play a critical role in the multiple beneficial properties of resveratrol. <i>Food and Chemical Toxicology</i> , 2020, 137, 111091.	1.8	25
46	Platinum Derivatives Effects on Anticancer Immune Response. <i>Biomolecules</i> , 2020, 10, 13.	1.8	55
47	Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. <i>Anticancer Research</i> , 2020, 40, 4011-4015.	0.5	4
48	Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure. <i>Pharmaceuticals</i> , 2020, 13, 416.	1.7	11
49	Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. <i>Oncimmunology</i> , 2020, 9, 1836766.	2.1	15
50	Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency. <i>Cancers</i> , 2020, 12, 3550.	1.7	12
51	Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. <i>Cancers</i> , 2020, 12, 2637.	1.7	40
52	Immunological features of coronavirus disease 2019 in patients with cancer. <i>European Journal of Cancer</i> , 2020, 139, 70-80.	1.3	13
53	Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy. <i>Cancers</i> , 2020, 12, 2418.	1.7	17
54	Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. <i>Cells</i> , 2020, 9, 2071.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	6.0	217
56	Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2699-2707.	1.2	9
57	Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 8, e000478.		15
58	Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2020, 12, 1429.	1.7	7
59	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. <i>Gut</i> , 2020, 69, 681-690.	6.1	79
60	Interleukin-1 $\beta$ and Cancer. <i>Cancers</i> , 2020, 12, 1791.	1.7	146
61	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	2.9	4
62	Implementation and use of whole exome sequencing for metastatic solid cancer. <i>EBioMedicine</i> , 2020, 51, 102624.	2.7	29
63	Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France. <i>Journal of Geriatric Oncology</i> , 2020, 11, 802-806.	0.5	14
64	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. <i>European Journal of Cancer</i> , 2020, 131, 40-50.	1.3	143
65	Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 167.	1.8	103
66	Red Wine Extract Disrupts Th17 Lymphocyte Differentiation in a Colorectal Cancer Context. <i>Molecular Nutrition and Food Research</i> , 2020, 64, 1901286.	1.5	10
67	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020, 26, 919-931.	15.2	118
68	Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3006-3006.	0.8	28
69	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 957-966.	3.2	37
70	Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy. <i>International Journal of Cancer</i> , 2019, 145, 3101-3111.	2.3	3
71	Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2357-2363.	1.2	17
72	Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. <i>Cancer Immunology Research</i> , 2019, 7, 1958-1969.	1.6	87

#	ARTICLE	IF	CITATIONS
73	Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?. <i>Frontiers in Immunology</i> , 2019, 10, 1816.	2.2	52
74	STAT3, a Master Regulator of Anti-Tumor Immune Response. <i>Cancers</i> , 2019, 11, 1280.	1.7	68
75	Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 97-106.	1.3	10
76	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	1.3	29
77	Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1 $\beta$ secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment. <i>Cell Death and Disease</i> , 2019, 10, 485.	2.7	34
78	Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. , 2019, 7, 160.		132
79	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodiges-14 Trial. <i>Cells</i> , 2019, 8, 516.	1.8	78
80	Cancer cells induce immune escape via glycoalyx changes controlled by the telomeric protein <sc>TRF</sc>. <i>EMBO Journal</i> , 2019, 38, .	3.5	49
81	Cell lines and immune classification of glioblastoma define patient's prognosis. <i>British Journal of Cancer</i> , 2019, 120, 806-814.	2.9	16
82	Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years. <i>European Journal of Cancer</i> , 2019, 111, 116-125.	1.3	20
83	HSP70 is a negative regulator of NLRP3 inflammasome activation. <i>Cell Death and Disease</i> , 2019, 10, 256.	2.7	81
84	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.	1.7	49
85	Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1564505.	2.1	118
86	Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 634-641.	0.8	2
87	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 75-85.	0.9	7
88	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1433981.	2.1	167
89	Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. <i>Nature Communications</i> , 2018, 9, 322.	5.8	226
90	Effect of Pharmaceutical Compounds on Myeloid-Derived Suppressor Cells. , 2018, , 199-213.		0

#	ARTICLE	IF	CITATIONS
91	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. <i>JAMA Oncology</i> , 2018, 4, 93.	3.4	303
92	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	6.0	3,689
93	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	0.8	70
94	RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer. , 2018, 6, 123.		31
95	Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors. <i>Anticancer Research</i> , 2018, 38, 5963-5968.	0.5	14
96	Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 1-61.	1.6	12
97	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2018, 119, 950-960.	2.9	133
98	5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. <i>Oncotarget</i> , 2018, 9, 11559-11571.	0.8	44
99	Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study. <i>Oncolimmunology</i> , 2018, 7, e1474319.	2.1	63
100	Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000375.	2.0	43
101	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1094-1106.	5.1	108
102	LPCAT2 controls chemoresistance in colorectal cancer. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1448245.	0.3	10
103	Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. <i>Oncotarget</i> , 2018, 9, 25617-25629.	0.8	10
104	FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2018, 9, 110-118.	0.9	9
105	Transcription Factor Binding Studies in CD4+ T Cells: siRNA Transfection, Chromatin Immunoprecipitation, and Liquid Luminescent DNA Precipitation Assay. <i>Methods in Molecular Biology</i> , 2017, 1585, 167-177.	0.4	0
106	Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation. <i>Cell Reports</i> , 2017, 19, 746-759.	2.9	104
107	Immune classifications with cytotoxic CD8 <sup>+</sup> and Th17 infiltrates are predictors of clinical prognosis in glioblastoma. <i>Oncolimmunology</i> , 2017, 6, e1321186.	2.1	21
108	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. <i>Oncolimmunology</i> , 2017, 6, e1339856.	2.1	8



#	ARTICLE	IF	CITATIONS
109	Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells. <i>Nature Communications</i> , 2017, 8, 559.	5.8	67
110	IRF8-dependent molecular complexes control the Th9 transcriptional program. <i>Nature Communications</i> , 2017, 8, 2085.	5.8	43
111	TH9 cells in anti-tumor immunity. <i>Seminars in Immunopathology</i> , 2017, 39, 39-46.	2.8	63
112	Antibiotic Use Does Not Appear to Influence Response to Nivolumab. <i>Anticancer Research</i> , 2017, 37, 3195-3200.	0.5	83
113	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. <i>Oncolmmunology</i> , 2016, 5, e1160193.	2.1	11
114	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX+Bevacizumab Drug Treatment Regimen. <i>Cancer Research</i> , 2016, 76, 5241-5252.	0.4	203
115	Peroxisome proliferator-activated receptor alpha deficiency impairs regulatory T cell functions: Possible application in the inhibition of melanoma tumor growth in mice. <i>Biochimie</i> , 2016, 131, 1-10.	1.3	18
116	Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3157-3165.	0.8	149
117	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	4.3	90
118	Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1054598.	2.1	144
119	HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1245-1246.	1.0	7
120	Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv330.	3.0	159
121	Human ectonucleotidase-expressing CD25 <sup>high</sup> Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. <i>Oncolmmunology</i> , 2016, 5, e1055444.	2.1	39
122	FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study "Prodige 14 " ACCORD 21 (METHEP-2), a unicancer GI trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3512-3512.	0.8	17
123	Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. <i>Oncotarget</i> , 2016, 7, 70948-70958.	0.8	43
124	Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. <i>Oncotarget</i> , 2016, 7, 9309-9321.	0.8	30
125	The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. <i>Journal of Hematology and Oncology</i> , 2015, 8, 52.	6.9	14
126	Effects of polyphenols and lipids from Pennisetum glaucum grains on T-cell activation: modulation of Ca <sup>2+</sup> and ERK1/ERK2 signaling. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 426.	3.7	27



#	ARTICLE	IF	CITATIONS
127	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. <i>Annals of Oncology</i> , 2015, 26, 1813-1823.	0.6	219
128	Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer. <i>Cancer Research</i> , 2015, 75, 475-479.	0.4	56
129	The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 354-360.	3.4	20
130	FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 " FFC0802). <i>Digestive and Liver Disease</i> , 2015, 47, 271-272.	0.4	13
131	Induction of pyroptosis in colon cancer cells by LXR <sup>2</sup> . <i>Molecular and Cellular Oncology</i> , 2015, 2, e970094.	0.3	15
132	Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2015, 33, 1263-1266.	1.2	5
133	Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. <i>Future Oncology</i> , 2015, 11, 2645-2654.	1.1	44
134	Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 228-235.	0.6	4
135	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	4.3	91
136	High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. <i>Surgery</i> , 2015, 157, 72-78.	1.0	29
137	Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXR <sup>2</sup> subcellular localization. <i>Oncotarget</i> , 2015, 6, 26651-26662.	0.8	27
138	Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients. <i>PLoS ONE</i> , 2014, 9, e105907.	1.1	14
139	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
140	Consensus guidelines for the detection of immunogenic cell death. <i>Oncotarget</i> , 2014, 3, e955691.	2.1	686
141	FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer. <i>Oncology</i> , 2014, 87, 148-158.	0.9	15
142	Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection. <i>Annals of Surgical Oncology</i> , 2014, 21, 1632-1640.	0.7	23
143	Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: A pooled analysis of two randomised trials. <i>European Journal of Cancer</i> , 2014, 50, 506-516.	1.3	41
144	The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. <i>Nature Immunology</i> , 2014, 15, 758-766.	7.0	187

#	ARTICLE	IF	CITATIONS
145	Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 141-150.	1.1	8
146	The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 19-30.	1.3	48
147	Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: A French population-based study. <i>Digestive and Liver Disease</i> , 2014, 46, 854-858.	0.4	46
148	Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1098-1116.	2.5	36
149	Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 1565.	1.4	22
150	The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. <i>Science</i> , 2013, 342, 971-976.	6.0	1,580
151	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. <i>Nature Medicine</i> , 2013, 19, 57-64.	15.2	634
152	Immune ambivalence. <i>Oncolmunology</i> , 2013, 2, e25737.	2.1	4
153	Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. <i>Journal of Investigative Dermatology</i> , 2013, 133, 499-508.	0.3	75
154	Immune effects of 5-fluorouracil. <i>Oncolmunology</i> , 2013, 2, e23139.	2.1	35
155	SOCS3 Transactivation by PPAR $\gamma$ Prevents IL-17 $\alpha$ -Driven Cancer Growth. <i>Cancer Research</i> , 2013, 73, 3578-3590.	0.4	51
156	Dacarbazine mediates antimelanoma effects via NK cells. <i>Oncolmunology</i> , 2013, 2, e23714.	2.1	15
157	STAT3 activation. <i>Jak-stat</i> , 2013, 2, e23010.	2.2	159
158	Socs3 induction by PPAR $\gamma$ restrains cancer-promoting inflammation. <i>Cell Cycle</i> , 2013, 12, 2157-2158.	1.3	8
159	Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells. <i>PLoS ONE</i> , 2013, 8, e65181.	1.1	103
160	Isolated Lung Perfusion as an Adjuvant Treatment of Colorectal Cancer Lung Metastases: A Preclinical Study in a Pig Model. <i>PLoS ONE</i> , 2013, 8, e59485.	1.1	6
161	Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies. <i>Future Oncology</i> , 2013, 9, 469-472.	1.1	11
162	Degarelix as a new antiangiogenic agent for metastatic colon cancer?. <i>World Journal of Gastroenterology</i> , 2013, 19, 769.	1.4	10

#	ARTICLE	IF	CITATIONS
163	Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunescape. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-9.	3.0	87
164	FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. <i>Annals of Oncology</i> , 2012, 23, 2552-2561.	0.6	31
165	Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 852-873.	0.9	76
166	High Pressure Enhances the Effect of Hyperthermia in Intraperitoneal Chemotherapy With Oxaliplatin. <i>Annals of Surgery</i> , 2012, 256, 1084-1088.	2.1	70
167	Controversies on the role of Th17 in cancer: a TGF- $\beta$ -dependent immunosuppressive activity?. <i>Trends in Molecular Medicine</i> , 2012, 18, 742-749.	3.5	75
168	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. <i>Science</i> , 2012, 337, 1678-1684.	6.0	367
169	Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. <i>Immunity</i> , 2012, 36, 362-373.	6.6	275
170	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. <i>Science Translational Medicine</i> , 2012, 4, 143ra99.	5.8	367
171	Role of myeloid-derived suppressor cells in tumor immunotherapy. <i>Immunotherapy</i> , 2012, 4, 43-57.	1.0	31
172	Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. <i>Investigational New Drugs</i> , 2012, 30, 758-764.	1.2	19
173	Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. <i>Journal of Neuro-Oncology</i> , 2012, 107, 351-358.	1.4	47
174	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. <i>Science</i> , 2011, 334, 1573-1577.	6.0	1,159
175	Contribution of IL-17 $\alpha$ -producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy. <i>Journal of Experimental Medicine</i> , 2011, 208, 491-503.	4.2	303
176	Tumor Exosome-Mediated MDSC Activation. <i>American Journal of Pathology</i> , 2011, 178, 1403-1405.	1.9	25
177	Harnessing dendritic cells in cancer. <i>Seminars in Immunology</i> , 2011, 23, 42-49.	2.7	53
178	Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murin model of peritoneal carcinomatosis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 4.	3.5	22
179	Feasibility and Safety of Weekly Sequential Epirubicin-Paclitaxel as Adjuvant Treatment for Operable Breast Cancer Patients Older than 70 Years. <i>Clinical Breast Cancer</i> , 2011, 11, 235-240.	1.1	4
180	Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 65-72.	1.1	115

#	ARTICLE	IF	CITATIONS
181	Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 909-918.	2.0	280
182	<i>In situ</i> immune response after neoadjuvant chemotherapy for breast cancer predicts survival. <i>Journal of Pathology</i> , 2011, 224, 389-400.	2.1	204
183	Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. <i>Anti-Cancer Drugs</i> , 2010, 21, 656-661.	0.7	17
184	Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. <i>Medical Oncology</i> , 2010, 27, 938-941.	1.2	5
185	Desirable cell death during anticancer chemotherapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1209, 99-108.	1.8	70
186	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 457-71.	3.9	761
187	5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity. <i>Cancer Research</i> , 2010, 70, 3052-3061.	0.4	1,098
188	Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. <i>Gut</i> , 2010, 59, 341-347.	6.1	195
189	Chemotherapy and radiotherapy: Cryptic anticancer vaccines. <i>Seminars in Immunology</i> , 2010, 22, 113-124.	2.7	183
190	Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. <i>Anticancer Research</i> , 2010, 30, 4317-23.	0.5	34
191	What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?. <i>Oncologist</i> , 2009, 14, 848-861.	1.9	109
192	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1627-1634.	2.0	207
193	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 $\beta$ -dependent adaptive immunity against tumors. <i>Nature Medicine</i> , 2009, 15, 1170-1178.	15.2	1,614
194	Sirinolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. <i>World Journal of Gastroenterology</i> , 2009, 15, 4278.	1.4	3
195	Immunogenic cancer cell death: a key-lock paradigm. <i>Current Opinion in Immunology</i> , 2008, 20, 504-511.	2.4	271
196	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1579-1587.	2.0	137
197	Immunological aspects of cancer chemotherapy. <i>Nature Reviews Immunology</i> , 2008, 8, 59-73.	10.6	1,374
198	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. <i>Clinical Cancer Research</i> , 2008, 14, 5242-5249.	3.2	104

#	ARTICLE	IF	CITATIONS
199	Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells. <i>Clinical Cancer Research</i> , 2008, 14, 2413-2420.	3.2	277
200	The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008, 118, 1991-2001.	3.9	520
201	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. <i>Journal of Clinical Investigation</i> , 2008, 118, 3751-3761.	3.9	56
202	Calreticulin exposure dictates the immunogenicity of cancer cell death. <i>Nature Medicine</i> , 2007, 13, 54-61.	15.2	2,580
203	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007, 13, 1050-1059.	15.2	2,657
204	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59.	2.8	491
205	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. <i>Journal of Molecular Medicine</i> , 2007, 85, 1069-1076.	1.7	68
206	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 641-648.	2.0	1,104
207	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. <i>Immunological Reviews</i> , 2006, 214, 229-238.	2.8	235
208	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	15.2	377
209	Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. <i>Journal of Immunology</i> , 2006, 176, 2722-2729.	0.4	192
210	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. <i>Journal of Experimental Medicine</i> , 2005, 202, 1691-1701.	4.2	1,224
211	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor- $\beta$ -dependent manner. <i>Journal of Experimental Medicine</i> , 2005, 202, 1075-1085.	4.2	806
212	Tumor cells convert immature myeloid dendritic cells into TGF- $\beta$ -secreting cells inducing CD4+CD25+ regulatory T cell proliferation. <i>Journal of Experimental Medicine</i> , 2005, 202, 919-929.	4.2	676
213	CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. <i>European Journal of Immunology</i> , 2004, 34, 336-344.	1.6	846